Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73

U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality

Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73

U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality

Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality

Plasma-cell dyscrasias (PCDs) are a group of neoplastic disorders characterized by the uninhibited expansion of a monoclonal population of malignant plasma cells. Multiple myeloma (MM) is the most common malignant plasma-cell tumor, accounting for about 1 percent of all cancer types,1 and the second most common hematologic malignancy in the United States. With an age-adjusted incidence rate of 5.5 cases per 100,000 population, an estimated 19,900 new diagnoses and 10,790 deaths due to myeloma occurred in 2007, according to the American Cancer Society. Although the median survival has improved to 5 years with current standards of treatment, the annual costs of modern therapies can range from $50,000 to $125,000 per patient. In PCDs, each abnormally expanded clone of malignant plasma cells produces an excess of either intact immunoglobulin or free light chains (FLCs) of a single type; either type of excess molecule is called a monoclonal protein (M protein) or paraprotein. Measurement of M proteins (either complete immunoglobulins or FLCs) is integral to diagnosing PCDs, monitoring disease response to therapy and adjusting treatment, and determining disease progression or relapse. The serum FLC (SFLC) assay (i.e., the Freelite® assay, The Binding Site Ltd., Birmingham, United Kingdom) was introduced in 2001 to measure the FLC component in serum. The assay works by recognizing an epitope that is detectable only on light chains that are not bound to the heavy chain of the immunoglobulin molecule—the FLCs—in the serum. This is the sole SFLC assay the U.S. Food and Drug Administration (FDA) has approved for use in the United States. The aim of this CER is to evaluate the present body of evidence addressing the relative effectiveness of the SFLC assay as compared with traditional tests for the diagnosis, management, and prognosis of PCDs. We sought to answer a set of questions focusing on the SFLC assay versus traditional testing in very specific clinical settings to focus on comparative effectiveness. Our goals were to evaluate the SFLC assay as an add-on test in diagnostic settings and to compare it with existing tests in other settings such as for disease monitoring and prognosis. Panels of Key Informants and Technical Experts, who helped identify the important areas for evidence review (as discussed in the Methods section), vetted these questions. To address these areas in an unbiased way that would permit summary of the relevant data, studies had to meet a specific, predefined set of criteria related to population, intervention (diagnostic test/disease monitoring), comparator, and outcome. This CER evaluates the SFLC assay as a diagnostic and prognostic tool adjunctive to the standard diagnostic tests for various PCDs. It addresses five Key Questions (KQs) that pertain to the (1) diagnosis of PCDs, (2) prognosis (i.e., progression from MGUS to MM and overall and disease-free survival in patients with a malignant PCD), (3) change in treatment decisions, (4) assessment of response to treatment, and (5) reduction of the need for other diagnostic tests (e.g., bone marrow biopsy).

Download and Read Free Online Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality

From reader reviews:

Kyle Raya:

Do you have something that you enjoy such as book? The publication lovers usually prefer to select book like comic, short story and the biggest an example may be novel. Now, why not striving Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 that give your pleasure preference will be satisfied through reading this book. Reading behavior all over the world can be said as the way for people to know world far better then how they react toward the world. It can't be mentioned constantly that reading addiction only for the geeky man but for all of you who wants to end up being success person. So , for all of you who want to start studying as your good habit, you are able to pick Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 become your current starter.

Maritza Berry:

Is it anyone who having spare time then spend it whole day simply by watching television programs or just lying down on the bed? Do you need something new? This Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 can be the respond to, oh how comes? A fresh book you know. You are therefore out of date, spending your extra time by reading in this brand new era is common not a geek activity. So what these publications have than the others?

Paul Williams:

E-book is one of source of know-how. We can add our understanding from it. Not only for students and also native or citizen require book to know the revise information of year for you to year. As we know those publications have many advantages. Beside we add our knowledge, can also bring us to around the world. By the book Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 we can have more advantage. Don't you to be creative people? For being creative person must prefer to read a book. Just choose the best book that acceptable with your aim. Don't be doubt to change your life at this time book Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73. You can more inviting than now.

Julie Chambers:

Some individuals said that they feel bored when they reading a book. They are directly felt that when they get a half portions of the book. You can choose the particular book Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review

Number 73 to make your reading is interesting. Your own skill of reading expertise is developing when you like reading. Try to choose simple book to make you enjoy to read it and mingle the idea about book and studying especially. It is to be 1st opinion for you to like to wide open a book and go through it. Beside that the book Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 can to be your new friend when you're sense alone and confuse in doing what must you're doing of these time.

Download and Read Online Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality #UIOJME6GF8L

Read Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality for online ebook

Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality Free PDF d0wnl0ad, audio books, books to read, good books to read, cheap books, good books, online books, books online, book reviews epub, read books online, books to read online, online library, greatbooks to read, PDF best books to read, top books to read Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality books to read online.

Online Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality ebook PDF download

Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality Doc

Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality Mobipocket

Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality EPub